Alpha Teknova, Inc. TKNO R2K
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 21.2% over 5 years.
CONS
- Revenue declined at -0.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 81 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TKNO Alpha Teknova, Inc. R2K | 5.40 | - | $289.52M | - | -17.17% | -23.92% | -0.73% | 21.21% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 8.98M | 9.08M | 8.31M | 9.39M | 11.15M | 11.69M | 10.69M | 9.12M | 11.53M | 8.17M | 9.29M | 9.61M | - | - | 9.79M | 10.29M | 10.45M | 9.98M | 11.08M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.79M | 6.30M | 7.25M | 6.74M | 7.29M |
| Gross Profit | 3.47M | 5.09M | 5.03M | 3.35M | 4.26M | 5.35M | 5.25M | 4.77M | 2.42M | 5.07M | 1.47M | 2.21M | 2.80M | - | - | 3.01M | 3.98M | 3.21M | 3.24M | 3.78M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.97M | 7.37M | 7.22M | 7.85M | 8.08M |
| Operating Income | 704.00K | 2.15M | -828.00K | -2.53M | -3.89M | -5.84M | -6.63M | -22.95M | -8.95M | -7.00M | -8.76M | -7.99M | -5.10M | - | - | -4.96M | -3.39M | -4.02M | -4.61M | -4.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.90M | -1.80M | -2.43M | -3.03M | -2.71M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 144.00K | 165.00K | 190.00K | 211.00K | 219.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.62M | -3.55M | -4.21M | -4.82M | -4.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.00K | 19.00K | 79.00K | -62.00K | 47.00K |
| Net Income | 512.00K | 1.53M | -655.00K | -2.25M | -3.25M | -5.50M | -6.20M | -22.47M | -8.82M | -7.15M | -10.15M | -8.10M | -5.36M | - | - | -4.64M | -3.57M | -4.29M | -4.76M | -4.55M |
| Diluted EPS | 0.02 | 0.07 | - | -0.52 | -0.12 | -0.20 | -0.22 | -0.80 | -0.31 | -0.25 | -0.34 | -0.20 | -0.13 | - | - | -0.09 | -0.07 | -0.08 | -0.09 | -0.08 |
| R&D Expense | 341.00K | 358.00K | 700.00K | 851.00K | 1.37M | 2.01M | 1.93M | 1.93M | 1.40M | 1.46M | 1.40M | 860.00K | 678.00K | 627.00K | - | 552.00K | 581.00K | 542.00K | - | 609.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 31.30M | - | 41.42M | 36.68M | 37.74M | 40.52M |
| Cost of Revenue | - | - | 23.94M | 26.39M | 30.51M | 27.08M |
| Gross Profit | 17.75M | - | 17.48M | 10.30M | 7.23M | 13.44M |
| Operating Expenses | - | - | 46.33M | 41.49M | 33.38M | 30.42M |
| Operating Income | 4.66M | - | -28.86M | -31.20M | -26.15M | -16.98M |
| EBITDA | - | - | -25.69M | -30.59M | -19.57M | -10.15M |
| Interest Expense | - | - | - | 833.00K | 687.00K | 710.00K |
| Pretax Income | - | - | -49.39M | -37.08M | -26.83M | -17.20M |
| Tax Provision | - | - | -1.92M | -298.00K | -88.00K | 58.00K |
| Net Income | 3.57M | - | -47.47M | -36.78M | -26.75M | -17.26M |
| Diluted EPS | 0.16 | - | -1.69 | -1.16 | -0.57 | -0.32 |
| R&D Expense | 1.51M | 4.31M | 7.74M | 5.57M | 2.76M | 2.20M |
Compounded Sales Growth
| 5 Years: | -0.73% |
| 1 Year: | 13.10% |
Compounded Profit Growth
| 5 Years: | 21.21% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -6.41% |
| 6 Months: | +16.13% |
| 3 Months: | +109.30% |
| 1 Month: | +67.18% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 62.91M | - | 152.26M | 128.59M | 118.77M | 103.58M |
| Current Assets | - | - | - | 61.14M | 45.66M | 42.78M | 34.51M |
| Cash & Equivalents | 4.14M | 3.31M | - | 42.24M | 28.48M | 3.71M | 5.91M |
| Inventory | - | - | - | 12.25M | 11.59M | 6.80M | 7.05M |
| Receivables | - | - | - | 4.26M | 3.95M | 4.31M | 4.62M |
| Total Liabilities | - | 10.51M | - | 52.38M | 38.55M | 36.38M | 34.81M |
| Current Liabilities | - | 3.96M | - | 10.88M | 8.88M | 11.21M | 7.54M |
| Long Term Debt | - | 0 | - | 21.98M | 13.25M | 9.44M | 13.12M |
| Total Debt | - | - | - | 42.31M | 30.46M | 30.17M | 28.27M |
| Total Equity | 12.91M | 16.77M | - | 99.89M | 90.04M | 82.39M | 68.78M |
| Shares Outstanding | - | - | - | 28.18M | 40.79M | 53.41M | 53.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.50M | - | -27.40M | -18.81M | -12.39M | -8.65M |
| Investing Cash Flow | -1.74M | - | -28.15M | -7.74M | -27.27M | 10.70M |
| Financing Cash Flow | -1.60M | - | 10.27M | 12.80M | 14.89M | 151.00K |
| Capital Expenditure | -5.47M | - | -28.15M | -7.93M | -1.12M | -1.15M |
| Free Cash Flow | -2.96M | - | -55.55M | -26.75M | -13.52M | -9.79M |
| Net Change in Cash | - | - | -45.28M | -13.75M | -24.78M | 2.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 56.7% | - | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating Margin % | 14.9% | - | -69.7% | -85.0% | -69.3% | -41.9% |
| Net Margin % | 11.4% | - | -114.6% | -100.3% | -70.9% | -42.6% |
| ROE % | 21.3% | - | -47.5% | -40.9% | -32.5% | -25.1% |
| ROCE % | 7.9% | - | -20.4% | -26.1% | -24.3% | -17.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Roubaix Capital, LLC | 3.51% | 1.88M | $10.16M |
| 2 | Royce & Associates LP | 1.99% | 1.07M | $5.77M |
| 3 | Blackrock Inc. | 1.34% | 716.77K | $3.87M |
| 4 | Millennium Management Llc | 0.83% | 447.14K | $2.41M |
| 5 | Vanguard Capital Management LLC | 0.82% | 441.88K | $2.39M |
| 6 | UBS Group AG | 0.61% | 325.16K | $1.76M |
| 7 | Conestoga Capital Advisors, LLC | 0.59% | 317.08K | $1.71M |
| 8 | Geode Capital Management, LLC | 0.57% | 307.87K | $1.66M |
| 9 | Bank of America Corporation | 0.43% | 228.29K | $1.23M |
| 10 | Massar Capital Management, LP | 0.37% | 200.00K | $1.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TKNO